Beta-lactam Pharmacokinetics in Secondary Care

NCT ID: NCT03033394

Last Updated: 2021-08-30

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 65 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-07-12
• Study Completion Date: 2019-08-01

Brief Summary

Currently in the UK, TDM is routinely performed for aminoglycosides and glycopeptide antimicrobial agents, given fears over the narrow therapeutic window of these agents and the serious adverse events associated with toxicity. However, in critical care the role of TDM for optimisation of therapy has been demonstrated to help optimise dosing of patients who tend to have variable pharmacokinetic parameters (J. A. Roberts et al,). This is of growing importance given that low concentrations of antimicrobial agents, below a micro-organisms minimum inhibitory concentration (MIC) is believed to be a major driver of AMR. The investigators set out to explore whether similar observations in PK-PD target variability are currently being observed across the secondary care setting (outside of critical care) and whether these appear to be impacting on clinical outcomes.

Detailed Description

STUDY PARTICIPANTS

• Participants receiving oral or intravenous therapy will be included in this study.
• Drug level sampling will be undertaken once the participant is at steady state (after at least 5 doses have been administered to those on treatment).
• All patients will be consented using the participation information leaflet and consent form provided in appendix 1.

DRUG LEVEL SAMPLING

• Patients will be identified for inclusion, and researchers will discuss inclusion in the study with the patient and provide clinical information for them to consider. Individuals will be recruited from all areas of secondary care (including, general medicine, general surgery, augmented care, and out-patient parenteral antimicrobial therapy [OPAT]).
• They will then be consented by researchers after being given at least 24 hours to consider this information and as long as the patient has expressed interest in participating to their treating physician.
• This will include permission for basic, anonymised demographic and clinical data to be collected related to the patients infection, for which they are receiving antimicrobial therapy.
• An extra 3mLs of blood will be collected during the patient's routine daily phlebotomy round following their consent. They will be enrolled for up to 72 hours or two days of routine blood tests (whichever is shorter). Up to 10 samples may be taken during the 2 days the patient is enrolled, depending on the number of routine blood tests the patient receives during that day. No more than 3mLs will be taken per each routine blood sample. For example, if the individuals will only have routine blood tests taken at 8am on day 1 and day 2. Then only two extra samples will be taken (3mLs on D1 and 3mLs on D2).
• The time they received their dose of antimicrobials, the length of infusion time (if available), and time the sample was collected will all be recorded.
• PK/PD indices for evaluation will be calculated post-hoc during pharmacokinetic-pharmacodynamic analysis. TDM sampling can occur at any time during the dosing schedule (in line with routine blood testing).
• A standard operating procedure for this study can be found in appendix 3.

SAMPLE PREPARATION AND ANALYSIS

• All blood samples will be allowed to clot and placed on ice. They will be centrifuged at 2,400rpm for 10 minutes. Sera from each sample will be separated into three vials and stored at -80C.
• Beta-lactam concentrations will be measured using validated high-performance liquid chromatography methods.
• Samples will be stored for up to three years post completion of data collection.

• Consent will be gained for samples to be used for calibration of electrochemical sensors in ex-vivo studies. This will be performed within 90 days of the samples being collected.

PHARMCOKINETIC-PHARMACODYNAMIC MODELLING

• Data will be anonymised and analysed using Pmetrics in R.
• Different pharmacokinetic models will be explored using in built statistical analysis options and visual predictive checks.
• Pharmacodynamic models will then be incorporated into the model using evidence identified in the literature for selection of parameters.
• Monte Carlo simulation will then be used to for simulation of target attainments and analysis of pharmacodynamic outcomes

Conditions

Pharmacokinetics; Beta Lactam Adverse Reaction; Penicillin Allergy

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Beta-lactam antibiotic

Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.

Beta-lactam antibiotic

Intervention Type: DRUG

Routine clinical dosing

Interventions

Beta-lactam antibiotic

Routine clinical dosing

Intervention Type: DRUG

Other Intervention Names

Penicillin

Eligibility Criteria

Inclusion Criteria

• Adult subjects over 18 years old
• Capacity to consent to participation
• Receiving target antimicrobial (amoxicillin, amoxcillin-clavulanate, cefuroxime, ceftriaxone, flucloxacillin, meropenem, piperacillin-tazobactam) for at least 5 doses prior to sampling
• Appropriate venous access (or for venous access to be gained)

Exclusion Criteria

• Children under 18 years old
• Lacking capacity or prisoner
• Anaemia or bleeding disorder, deemed significant by the patients physician
• Patient's physician deems that they are not suitable for inclusion in the study
• Patients unlikely to be receiving agent for study period

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Imperial College London

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alison H Holmes, MD MPH MBBS

Role: PRINCIPAL_INVESTIGATOR

Health Protection Research Unit in HCAI & AMR

Locations

Hammersmith Hospital

London, , United Kingdom

Countries

United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Other Identifiers

16/LO/2179

Identifier Type: OTHER

Identifier Source: secondary_id

33017

Identifier Type: OTHER

Identifier Source: secondary_id

207217

Identifier Type: -

Identifier Source: org_study_id